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 Introduction 
 The lymphatic vascular system has an important role 
in the maintenance of tissue fluid homeostasis, intestinal 
lipid absorption and immune surveillance in that it re-
cruits and transports immune cells from peripheral tis-
sues to the regional lymph nodes  [1, 2] . There have been 
many studies into the role of the lymphatic system in pro-
moting metastasis to lymph nodes and beyond  [3–5] , and 
in modulating inflammatory diseases  [6, 7] . Much prog-
ress has been made following the identification of spe-
cific lymphatic markers that distinguish lymphatic endo-
thelial cells from blood vascular endothelial cells and 
novel molecular mediators of lymphatic vessel growth 
and differentiation, as well as developmental studies in 
mouse models  [1, 2] .
 There is considerable evidence that during mamma-
lian embryonic development, the lymphatic vascular sys-
tem predominantly develops from pre-existing embry-
onic veins. In mice, expression of the lymphatic vessel 
endothelial hyaluronan receptor-1 (LYVE-1) at embry-
onic day (ED) 9–9.5 by the endothelial cells that line the 
anterior cardinal veins is considered to be the first mor-
phological indication that venous endothelial cells have 
acquired the competence to respond to an unidentified 
lymphatic-inducing signal  [8] . The biological function of 
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 Abstract 
 The molecular mechanisms that regulate the earliest steps 
of lymphatic vascular system development are unknown. To 
identify regulators of lymphatic competence and commit-
ment, we used an in vitro vascular assay with mouse embry-
onic stem cell-derived embryoid bodies (EBs). We found that 
incubation with retinoic acid (RA) and, more potently, with 
RA in combination with cAMP, induced the expression of the 
lymphatic competence marker LYVE-1 in the vascular struc-
tures of the EBs. This effect was dependent on RA receptor 
(RAR)-  and protein kinase A signaling. RA-cAMP incubation 
also promoted the development of CD31+/LYVE-1+/Prox1+ 
cell clusters. In situ studies revealed that RAR-  is expressed 
by endothelial cells of the cardinal vein in ED 9.5–11.5 mouse 
embryos. Timed exposure of mouse and  Xenopus embryos 
to excess of RA upregulated LYVE-1 and VEGFR-3 on embry-
onic veins and increased formation of Prox1-positive lym-
phatic progenitors. These findings indicate that RA signaling 
mediates the earliest steps of lymphatic vasculature devel-
opment.  Copyright © 2010 S. Karger AG, Basel 
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LYVE-1 is unknown; LYVE-1-deficient mice have no ma-
jor lymphatic or other abnormalities  [9, 10] . At approxi-
mately ED 9.5, a restricted subpopulation of endothelial 
cells on one side of the cardinal vein expresses the tran-
scription factor Prox-1, indicating that this is the stage of 
lymphatic commitment  [11] . These Prox1-positive cells 
then bud off from the cardinal veins and migrate away to 
finally form the primitive lymph sacs. Prox1-deficient 
mice completely lack a lymphatic vascular system  [11] . 
Vascular budding and migration appear to occur under 
the guidance of local gradients of vascular endothelial 
growth factor (VEGF)-C, which activates its receptor, 
VEGFR-3, on lymphatic precursor cells  [12] . VEGF-C-
deficient mice also lack lymphatic vasculature and un-
dergo prenatal death because of pronounced fluid accu-
mulation in the tissues  [12] . It was recently shown that the 
transcription factor Sox18 is expressed in a subset of the 
cardinal vein cells that later become Prox1-positive lym-
phatic progenitor cells and that Sox18 directly activates 
Prox1 transcription  [13] .
 Studies in genetic mouse models indicate that follow-
ing the formation of the lymph sacs, the separation of the 
lymphatic and venous system is mediated by the tyrosine 
kinase Syk and the adaptor protein SLP-76  [14, 15] , the 
sprouty-related ena/VASP homology 1 domain-contain-
ing proteins (spred) 1 and 2  [16] , and angiopoietin-like 
protein 4  [17] . Further lymphatic vessel maturation and 
remodeling are controlled by a plethora of molecules [for 
review, see  2 ] that includes the transcription factor Foxc2 
 [18] , angiopoietin-2  [19, 20] , the non-kinase receptor neu-
ropilin-2  [21] , ephrin B2  [22] and the transmembrane gly-
coprotein podoplanin  [23] .
 Despite advances in our understanding of lymphatic 
vasculature development, the molecular mechanisms 
that control the earliest stages of lymphatic competence 
(expression of LYVE-1 by endothelial cells of the cardinal 
vein and lymphatic precursor cells) have not been deter-
mined. To identify pathways that mediate lymphatic 
competence, we used a previously established embryoid 
body (EB)-based vascular differentiation assay  [24] as a 
screening model. This system assesses the ability of 
mouse EB cells to differentiate into lymphatic vessel-like 
structures that express the panvascular marker CD31, as 
well as Prox1 and LYVE-1  [24] ; it was previously used to 
characterize the ability of VEGF-C to promote in vitro 
lymphangiogenesis  [24, 25] . Using this model system, we 
investigated the potential effects of soluble factors that 
have been previously reported to be potentially associated 
with activity on lymphatic endothelial cells in vitro or in 
vivo. We also investigated the effects of retinoic acid 
(RA), since RA has been shown to be involved in a pleth-
ora of developmental differentiation processes, including 
vascular differentiation  [26–28] .
 In our study, the growth factors VEGF-C, growth hor-
mone, insulin-like growth factor (IGF)-1 and interleukin 
(IL)-7 were found to moderately induce the expression of 
LYVE-1 in EBs. Incubation of EBs with RA and, more 
potently, a combination of RA and cyclic AMP (cAMP), 
induced LYVE-1 expression in the vascular structures; 
this effect depended on RA receptor (RAR)-  and pro-
tein kinase A (PKA) signaling. In situ studies revealed 
that RAR-  is highly expressed by endothelial cells of the 
cardinal vein from ED 9.5–11.5 in mice, in areas of LYVE-
1 expression. Most importantly, timed exposure of mouse 
embryos and of  Xenopus laevis tadpoles to RA resulted in 
potent upregulation of LYVE-1 and VEGFR-3 on embry-
onic veins and lymph sacs. Together, these findings indi-
cate that RA signaling could mediate the earliest steps of 
lymphatic vasculature development.
 Materials and Methods 
 Mouse Embryonic Stem Cell Culture, Establishment and 
Treatment of EBs 
 Murine C57BL/6x129SvEv-derived (passage 3–12) embryonic 
stem cells (kindly provided by N. Gale, Regeneron Pharmaceuti-
cals, Tarrytown, N.Y., USA) were cultured on mitotically inacti-
vated primary mouse embryonic fibroblasts (passage 2–5; Insti-
tute of Laboratory Animal Science, University of Zurich, Switzer-
land) in Dulbecco’s modified Eagle medium (Gibco, Eggenstein, 
Germany), supplemented with 18% fetal bovine serum (Gibco), 
100 n M sodium pyruvate (Sigma, Buchs, Switzerland), MEM vi-
tamins, 2 m M  L -glutamine, streptomycin and penicillin (all from 
Gibco), 10 m M 2-mercaptoethanol and 2,000 U/ml recombinant 
leukemia inhibitory factor (LIF; Chemicon International, Te-
mecula, Calif., USA). Primary mouse embryonic fibroblasts and 
LIF were removed and murine embryonic stem cells were trans-
ferred to suspension culture for EB formation as described  [29] . 
After 3 or 4 days, EBs of the same size (approximately 500   m in 
diameter) were transferred into 12-well dishes (1 EB per well; BD 
Bioscience, San Diego, Calif., USA) and cultured for 14 days with-
out LIF. Then, EBs were incubated with or without the following 
factors for 2, 4, 6, 8, 10, 12 or 14 days: 20 ng/ml recombinant hu-
man VEGF-A (VEGF-A 165; kindly provided by the National 
Cancer Institute, Bethesda, Md., USA); 200 ng/ml recombinant 
human VEGF-C (R&D Systems, Minneapolis, Minn., USA); 20 
ng/ml human fibroblast growth factor-2 (kindly provided by the 
National Cancer Institute); 1 mg/ml hyaluronic acid sodium salt 
from human umbilical cord (Fluka, Buchs, Switzerland); 100 ng/
ml recombinant human IGF-1 (R&D Systems); 25 ng/ml recom-
binant human IL-3 (Chemicon International); 30 ng/ml human 
hepatocyte growth factor (R&D Systems); 20 ng/ml human plate-
let growth factor (R&D Systems); 50 ng/ml human growth hor-
mone (R&D Systems); 20 ng/ml recombinant human IL-7 (Chem-
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icon International); 100   M S-nitroso- N -acetylpenicillamine 
(Sigma); 10 m M human endothelin-3 (R&D Systems); 1, 2.5, 5, 10 
or 100   M all-trans-RA (Sigma); 10   M 4-[E-2-(5,6,7,8-tetrahy-
dro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic 
acid (Sigma); 1 or 10   M 13-cis-RA (Sigma); 0.5 m M  N -6,2  -O-
dibutyryl-adenosine 3  ,5  -cyclic monophosphate (cAMP; Fluka); 
10   M Ro 41-5253 (BioMol International, Plymouth Meeting, Pa., 
USA); 10   M  N -[2-(p-bromocinnamylamino)ethyl]-5-isoquino-
line sulfonamide, Di-HCl salt (H89; Calbiochem, San Diego, 
 Calif., USA). EBs were fixed in –20   °   C cold 100% methanol or in 
4% paraformaldehyde at 4  °  C for 10 min.
 Endothelial Cell Culture, Real-Time RT-PCR, FACS and 
Immunostains 
 Human umbilical vein endothelial cells (HUVECs), obtained 
from ScienceCell Research Labs (San Diego, Calif., USA) were 
seeded into fibronectin-coated culture dishes (10   g/ml; BD Bio-
sciences, Bedford, Mass., USA) and were cultured in endothelial 
cell basal medium (Cambrex Bio Science, Walkersville, Md., 
USA) supplemented with 20% fetal bovine serum (Invitrogen, 
Grand Island, N.Y., USA), 2 m M  L -glutamine, antibiotic-antimy-
cotic solution, 10   g/ml hydrocortisone and  N -6,2  -O-dibutyryl-
adenosine 3  ,5  -cyclic monophosphate (25   g/ml; all from Fluka). 
Cells from passages 6–10 were used. HUVECs were incubated for 
24 h with 10   M RA plus 0.5 m M cAMP or with DMSO as nega-
tive control. Then real-time RT-PCR, FACS and immunostaining 
were performed. For real-time RT-PCR analyses, total cellular 
RNA was isolated using the Trizol reagent (Invitrogen) and was 
extracted with chloroform, precipitated with isopropanol, washed 
with 70% ethanol, and dissolved in DNase-free/RNase-free dis-
tilled water. The concentration of RNA was measured using a 
NanoDrop ND-1000 spectrophotometer (Witec AG, Littau, Swit-
zerland). The expression of LYVE-1 and Prox1 mRNA was quan-
tified by TaqMan real-time RT-PCR using the AB 7900 HT fast 
real-time PCR system (Applied Biosystems, Foster City, Calif., 
USA). The following probes and primers were used: LYVE-1 
 forward primer (FP) 5  -AGCTATGGCTGGGTTGGAGA-3  , re-
verse primer (RP) 5  -CCCCATTTTTCCCACACTTG-3  , probe 
5  -FAM-TTCGTGGTCATCTCTAGGATTAGCCCAAACC-
BKH1-3  ; Prox1: FP 5  -ACAAAAATGGTGGCACGGA-3  , RP 5  -
CCTGATGTACTTCGGAGCCTG-3  , probe 5  -FAM-CCCA G-
TT T CCAAGCCAGCGGTCTCT-BKH1-3  . Each reaction was 
normalized for the expression of   -actin (FP 5  -TCAC CGA GC-
GCGGCT-3  , RP 5  -TAATGTCACGCACGATTTCCC-3  , probe 
5  -JOE-CAGCTTCACCACCACGGCCGAG-TAMRA-3  ). Stu-
dent’s t test was performed in Office Excel. For FACS analysis, 
cells were stained with rabbit anti-human LYVE-1 antibody (Re-
liaTec, Braunschweig, Germany; working concentration: 3   g/
ml), anti-rabbit fluorescein isothiocyanate or isotype control an-
tibodies (CALTAG/Invitrogen, Basel, Switzerland), and FACS 
was performed using a BD FACSCanto (BectonDickinson, Basel, 
Switzerland) and the FACSDiva software. Data were analyzed 
with Flowjo software (Treestar, Ashland, Tenn., USA). For im-
munostains, cells were stained with human LYVE-1 antibody 
(ReliaTec; working concentration 1.5   g/ml) and human Prox1 
antibody (kindly donated by Prof. K. Alitalo), and corresponding 
secondary antibodies were labeled with Alexa-Fluor 488 or 594 
(Molecular Probes, Eugene, Oreg., USA; working dilution 1: 200). 
Cell nuclei were counterstained with Hoechst bisbenzimide (Sig-
ma). Negative controls using isotype control IgG instead of the 
primary antibodies showed little or no background staining (data 
not shown). All experiments were performed three times with 
comparable results.
 Immunofluorescence and Quantitative Analysis of Vessel 
Development in EBs 
 EBs (9 per group) were stained with antibodies against mouse 
LYVE-1 (Angiobio, Del Mar, Calif., USA; R&D Systems; working 
dilution 1: 500), CD31 (BD Bioscience; working dilution 1: 50) or 
Prox1 (kindly provided by Dr. Kari Alitalo, Helsinki, Finland; 
working dilution 1: 100), and corresponding secondary antibodies 
were labeled with Alexa-Fluor 488 or 594 (Molecular Probes). Cell 
nuclei were counterstained with Hoechst bisbenzimide (Sigma-
Aldrich). Negative controls using isotype control IgG instead of 
the primary antibodies showed little or no background staining 
(data not shown). LYVE-1/CD31-stained sections were examined 
with a Zeiss Axiovert 200M microscope, and images were cap-
tured with a Zeiss AxioCam-MRm (Carl Zeiss, Oberkochen, Ger-
many). Image acquisition in the individual fluorescent channels 
was accomplished using Axio Vision 4.4 software (Zeiss). Adobe 
Photoshop CS3 (Adobe Systems, San Jose, Calif., USA) was used 
to adjust image brightness and for image overlay. Computer-as-
sisted morphometric vessel analyses were performed using the 
IP-LAB software (Scanalytics, Fairfax, Va., USA). The total EB 
area was examined and the total vessel area and the total number 
of vessels per EB were determined on differential immunofluo-
rescence stains (CD31/LYVE-1). The average vessel area and aver-
age vessel number per group were then calculated and statistical 
analysis was performed using the unpaired Student’s t test. Prox1/
LYVE-1/CD31-positive cell cluster imaging and quantification 
was done with a Delta Vision microscope at  ! 20, and the 3-di-
mensional images were captured with a Roper CoolSnap HQ 
camera and analyzed with DeltaVision Analysis Software (Ap-
plied Precision SoftWoRx, Issaquah, Wash., USA) for deconvolu-
tion.
 Immunohistochemistry of Mouse Embryo Sections 
 FVB mice (12–16 weeks of age; 2 estrous females and 1 male 
per cage) were allowed to breed overnight. Females with detect-
able vaginal plugs on the next morning were determined to be at 
day 0 of pregnancy. Pregnant mice were housed individually. The 
pregnant mice were sacrificed by CO 2 at days 9.5, 10.5 and 11.5 of 
pregnancy. The embryos were removed by laparotomy. All em-
bryos were immediately fixed in 4% paraformaldehyde at 4  °  C for 
48 h, then dehydrated in ethanol series, cleared in xylene and em-
bedded in paraffin wax. Serial cross-sections (10   m) of the em-
bryos were cut and mounted on glass slides. After they were de-
waxed in xylene, sections were hydrated and processed for immu-
nohistochemistry for LYVE-1 (goat biotinylated anti-mouse; 
R&D Systems; working dilution 1: 10) and RAR-  (rabbit anti-
mouse; Santa Cruz Biotechnology; working dilution 1: 50). In ad-
ditional experiments, RA (Sigma-Aldrich) or Ro 41.5253 (BioMol 
International) were dissolved in corn oil right before use; preg-
nant mice (5 per treatment group) were given two intraperitoneal 
injections of 25 mg/kg of body weight of RA or of 50 mg/kg body 
weight of Ro 41-5253 in corn oil on days 8 and 10 of pregnancy. 
 Control mice (n = 5) received an equal volume of corn oil. Mice 
were sacrificed on day 11.5 of pregnancy. Embryos were embed-
ded in paraffin wax or frozen in OCT (Sakura FineTek, Torrance, 
Calif., USA). Serial cross-sections of the embryos were cut at a 
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thickness of 10   m (paraffin) or 15   m (frozen sections) and were 
mounted on glass slides. Paraffin sections were processed for 
LYVE-1 immunohistochemistry as described above. The sections 
were exposed to AEC (3-amino-9-ethylcarbazole) chromogen 
that forms a red end product at the site of the antigen and the re-
action was stopped after 1 min incubation. Frozen sections were 
fixed in 100% methanol at –20   °   C for 10 min and then processed 
for immunofluorescence staining for Prox1 (kindly donated by 
Prof. K. Alitalo) and CD31 (BD Bioscience), using corresponding 
secondary antibodies labeled with Alexa-Fluor 488 or 594 (Mo-
lecular Probes). Cell nuclei were counterstained with Hoechst bis-
benzimide. Negative controls using isotype control IgG instead of 
the primary antibodies showed little or no background staining 
(data not shown). The stained sections were examined with a 
Zeiss Axioskop 2 mot plus. All images were captured with a Zeiss 
AxioCam-MRm. The quantification of LYVE-1 expression was 
performed using Photoshop C3; the number of selected LYVE-1-
stained pixels was determined and their percentage per total pix-
el number per picture (LYVE-1 area fraction) was then deter-
mined. The jugular lymph sac area quantification was performed 
using the area measurement tool of Photoshop C3. The quantifi-
cation of CD31+/Prox1+ cells was performed by counting the 
number of CD31+/Prox1+ cells per picture. Three sections per 
embryos and 4 embryos from 4 different pregnant mice were an-
alyzed.
 X. laevis Embryos and in situ Hybridization 
 In vitro fertilization, culture and staging of  X. laevis embryos 
(tadpoles) were performed as previously described  [30, 31] . Em-
bryos were cultured in 0.1 ! MMR (0.1  M NaCl, 2 m M KCl, 1 m M 
MgSO 4 , 2 m M CaCl 2 , 5 m M HEPES and 0.1 m M EDTA) at 22   °   C 
until stage 28. Thereafter, 20   M RA plus 1 m M cAMP or DMSO 
was added to the medium. In addition, tadpoles were also bathed 
with Ro 41-5253 (concentration range 100 n M to 20   M ), but the 
treatment resulted in lethality within the first 4 h of exposure. 
Embryos were fixed at stage 39 in 4% formalin for 1 h. Probe syn-
thesis, whole-mount in situ hybridization and bleaching of em-
bryos were carried out as described previously  [31–33] . For in situ 
hybridization, probe synthesis, whole-mount in situ hybridiza-
tion and bleaching of embryos were carried out as described  [31–
33] . Digoxigenin probes were generated from linearized plasmids 
encoding for LYVE-1, Prox1, VEGFR-3 and CD31. Digital photo-
graphs of stained embryos were taken with an AxioCam Color 
camera mounted on a Zeiss Stereo Lumar.V12 stereoscopic micro-
scope.
 Results 
 RA Promotes Lymphatic Differentiation of EBs 
 We used the EB vascular differentiation assay to iden-
tify regulators of the early steps of lymphatic vascular sys-
tem development  [24] . We first investigated the effects of 
several candidate molecules on the number and size of 
CD31+/LYVE-1+ vessel-like structures. The factors were 
added to EBs, starting at day 14 after initiation, for up to 
10 days. In accordance with previous results  [24, 25] , 
VEGF-C promoted the formation of CD31+/LYVE-1+ 
vascular structures, compared with the vehicle control. 
The maximum induction occurred on day 4 of exposure 
(data not shown), so this was chosen as the study period 
for further investigations.
 Incubation of EBs with VEGF-C, growth hormone, 
IGF-1 and IL-7 significantly promoted the expression of 
LYVE-1 in CD31+ structures ( fig. 1 a). Incubation of EBs 
with 10   M RA and, even more potently, with a combi-
nation of RA and cAMP, resulted in an enlarged area
of CD31+/LYVE-1+ structures, compared to controls 
( fig. 1 a). The cAMP concentration of 0.5   M was chosen 
based on the results of a previous study in mouse endo-
thelial progenitor cells  [34] . Only VEGF-C and RA, with 
or without cAMP, also significantly promoted the num-
ber of CD31+/LYVE-1+ structures ( fig. 1 b). The effects of 
RA at 1   M were less pronounced than at 10   M (data not 
shown). In contrast, no major effects on the total area or 
number of CD31+/LYVE-1+ structures were detected af-
ter incubation with placental growth factor, hepatocyte 
growth factor, IL-3 or the nitric oxide donor S-nitroso-N-
acetyl-l,l-penicillamine. cAMP did not enhance VEGF-C 
effect and incubation with cAMP alone had no effect on 
EBs vasculature ( fig. 1 a). In agreement with a specific role 
of retinoic receptors, we found that in addition to RA, 
13-cis-RA (+ cAMP) and the synthetic retinoid analogue 
TTBNP (+ cAMP) also promoted significant formation 
of LYVE-1+/CD31+ area ( fig. 1 c).
 Incubation of EBs with RA significantly increased the 
EB area covered by CD31+/LYVE-1+ structures ( fig. 2 d–
f) and, in agreement with the documented synergistic ef-
fect of RA and cAMP in other systems  [34–36] , the com-
bination of RA and cAMP for 4 days resulted in LYVE-1 
expression by most of the CD31+ endothelial cells (78.6 + 
14%;  fig.  2 g–o), compared to 27 + 14% in control EBs 
( fig. 2 a–c). A quantitative analysis revealed that the RA + 
cAMP treatment significantly increased the total CD31+ 
area and the CD31+/LYVE-1+ area, but not the CD31+/
LYVE-1– area, as compared with controls ( fig. 2 p), thus 
excluding the possibility that the observed increase in 
LYVE-1 expression might be a secondary effect due to an 
overall increased amount of CD31+ vascular structures.
 Importantly, incubation of EBs with RA and cAMP
for up to 4 days significantly increased the number
of Prox1+/LYVE-1+/CD31+ cell clusters formed ( fig.
3 e–j; see online supplementary figure S1E–H, www.
karger.com/doi/10.1159/000320620), whereas only a few 
individual Prox1+/LYVE-1+/CD31+ cells, but no cell 
clusters, were detected in control EBs ( fig. 3 a–d, j; online 
suppl. fig. S1A–D).
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 Fig. 1. The in vitro mouse EB assay reveals that RA and cAMP 
induce LYVE-1 expression. Mouse EBs were cultured for 14 days 
and were then incubated with compounds for 4 days. 10   M all-
trans-RA (RA) and RA + 0.5 m M cAMP (RA + cAMP) increased 
the LYVE-1+ area among CD31+ vessel-like structures ( a ). VEGF-
C, IGF-1, GH and IL-7 also showed a significant induction of 
LYVE-1 expression ( a ). 10   M all-trans-RA + cAMP and VEGF-C 
induced the formation of several distinct LYVE1+ lymphatic ves-
sel-like structures ( b ). 13-cis-RA + cAMP and the synthetic reti-
noid TTBNP (+ cAMP) increased the area of LYVE-1 expression 
( c ). Exposure of EBs to Ro 41-5253, an inhibitor of RAR-  , in com-
bination with RA + cAMP inhibited the expression of LYVE-1 in 
CD31+ vessel-like structures. H69, an inhibitor of PKA, also in-
hibited the effects of RA + cAMP. Ro 41-5253 did not significant-
ly inhibit the VEGF-C effect. EBs exposed to the inhibitors alone 
expressed the same levels of LYVE-1 as controls. Data are ex-
pressed as mean values + SEM (n = 5).  *  p  ! 0.05;  * *  p  ! 0.01;
 * * *  p  ! 0.001. 
 Fig. 2. Incubation of EBs with RA and cAMP induces LYVE-1 ex-
pression in CD31+ vessel-like structures. Differential immuno-
fluorescence analysis of control EBs for expression of CD31 and 
LYVE-1 showed the formation of CD31+/LYVE-1– blood vessel-
like structures, whereas only a few endothelial cells expressed 
LYVE-1 ( a–c ). Incubation with RA induced LYVE-1 expression in 
the CD31+ structures ( d–f ). RA in combination with cAMP
(RA + cAMP) further increased the CD31+/LYVE-1+ area ( g–p ). 
The total CD31+ and the CD31+/LYVE-1+ area, but not the 
CD31+/LYVE-1– area was increased ( p ). Data are expressed as 
mean values + SEM (n = 9). Scale bars = 100   m.  
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 We next investigated whether the effects of RA and 
cAMP on the formation of lymphatic vessel-like struc-
tures were inhibited by the RAR-  -specific antagonist Ro 
41-5253. Incubation of EBs with Ro 41-5253 alone did not 
affect the formation of CD31+/LYVE-1+ or CD31+/
LYVE-1+/Prox1+ structures, whereas Ro 41-5253 potent-
ly inhibited the induction of lymphatic vessel-like struc-
tures by RA and cAMP ( fig. 1 c;  table 1 ). The cAMP-de-
pendent PKA inhibitor H89 also completely blocked the 
induction of CD31+/LYVE-1+/Prox1+ structures by RA 
and cAMP; incubation of EBs with H89 alone had no ef-
fects ( fig. 1 c;  table 1 ). Together, these findings indicate a 
sufficient role of the RAR-  and cAMP-PKA pathway in 
promoting the retinoid effects on lymphatic differentia-
tion in the mouse EB assay.
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 Fig. 3. Incubation of EBs with RA and cAMP increases formation 
of Prox1+/LYVE-1+/CD31+ cell clusters. Double immunofluores-
cence analysis revealed that incubation with RA and cAMP in-
duced expression of Prox1 (cell nucleus staining;  f ,  g ,  h ,  i ) in 
CD31+ (cell membrane staining;  e ,  g ,  i ) and in LYVE-1+ (online 
suppl. fig. 1E–H) endothelial cell clusters, compared with control 
EBs where only a few Prox1+ ( b–d ) and CD31+ ( a ,  c ) cells were 
visible. Cell nuclei are visible in  d and  h . Pictures were obtained 
after 2 days of exposure to RA and cAMP. Quantitative analysis 
revealed that daily treatment with RA and cAMP increased the 
number of CD31+/Prox1+ cell clusters in EBs compared with neg-
ative controls, beginning at 1 day after treatment initiation ( j ). 
Data are expressed as mean values + SEM (n = 5). Scale bars = 50 
  m.  *  p  ! 0.05;  * *  p  ! 0.01;  * * *  p  ! 0.001. 
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 In vivo Effects of RA in Developing Mouse Embryos 
 We investigated whether RA could affect in vivo 
 development of the mouse lymphatic vascular system. 
Immunohistochemical analyses were used to determine 
whether RA receptors are expressed by endothelial cells 
of the cardinal vein of mouse embryos at ED 9.5–11.5, 
when expression of LYVE-1 and Prox1 is first observed. 
We found that RAR-  was expressed ( fig.  4 d, arrow-
heads) by the endothelial cells of the LYVE-1+ cardinal 
vein ( fig. 4 c, arrowheads) and by the developing lymph 
sacs at ED 11.5. In fact, RAR-  was expressed on/nearby 
the cardinal veins by ED 10.5 ( fig. 4 e) and 9.5 ( fig. 4 f), 
time points at which the jugular lymph sacs had not yet 
formed.
 Based on the observed expression pattern of RAR-  
during lymphatic development, we investigated whether 
RA also induced in vivo expression of LYVE-1 and Prox1. 
To this end, we injected RA intraperitoneally into preg-
nant mice, to expose the developing embryos to an in 
utero excess of RA. RA (25 mg/kg of weight) was injected 
on days 8 and 10 of pregnancy. ED 8 was chosen as the 
first injection time point to ensure RA exposure before 
LYVE-1 and Prox1 were expressed by cardinal vein endo-
thelium (at ED 9). ED10 was chosen for the second injec-
tion to ensure that lymphatic-committed endothelial 
cells were exposed to excess RA as they were budding 
from the cardinal veins.
 At ED 11.5, when the first jugular lymph sacs are vis-
ible, immunohistochemistry with a short 1-min colori-
metric reaction revealed strong LYVE-1 expression on 
the cardinal vein endothelial cells of embryos that were 
exposed to RA in utero ( fig. 5 d–f) but not of control em-
bryos ( fig. 5 a–c). A quantitative analysis confirmed that 
LYVE-1 expression was significantly upregulated upon 
treatment ( fig. 5 j). We also observed an increase in the 
size of the primary jugular lymph sacs in embryos ex-
posed to RA ( fig. 5 k; p = 0.19). In contrast, in utero expo-
sure of the embryos to Ro 41-5253, an inhibitor of RAR-  , 
led to a decrease in LYVE-1 expression by the ECs of the 
cardinal vein and of the jugular lymph sac ( fig. 5 g–j), as 
compared to control embryos ( fig. 5 a–c, j). The lymph sac 
area was not affected by Ro 41-5253 ( fig. 5 k). Importantly, 
differential immunofluorescence analyses of CD31 and 
Prox1 expression revealed that embryonic exposure to 
RA increased the number of Prox1+ endothelial cells in 
the cardinal veins and of sprouting Prox1+ cells that form 
the lymph sacs ( fig. 6 g–l), compared with control embry-
os ( fig. 6 a–f). A quantitative analysis confirmed that the 
number of CD31+/Prox1+ cells in the jugular area of the 
embryos significantly increased upon RA treatment 
( fig.  6 r), whereas injection of Ro 41-5253 slightly de-
creased the number of CD31+/Prox1+ cells ( fig. 5 m–r) as 
compared to controls ( fig. 6 a–f, r). The increase in CD31+/
Prox1+ cells in the cardinal veins was not due to en-
hanced cell proliferation, as revealed by the results of 
phosphohistone 3 stains (data not shown). ED 11.5 em-
bryos, at gross examination, showed a slight increase in 
blood presence in the extra-embryonic tissues, a lower 
amount of blood in the heart region as well as a lower 
heartbeat frequency (data not shown). The treatment also 
caused a mild reduction of the caudal length as previ-
ously shown  [37] (data not shown).
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 Fig. 4. RAR-  is expressed by endothelial cells of the cardinal 
veins of mouse embryos. Immunohistochemical analysis of 
mouse embryos for LYVE-1 ( a ,  c : ED 11.5) and RAR-  ( b ,  d : ED 
11.5;  e : ED 10.5;  f : ED 9.5) revealed that RAR-  ( b ,  d , arrowheads) 
is expressed by/near the endothelial cells of the LYVE-1+ ( a ,  c , ar-
rowheads) cardinal veins and forming jugular lymph sacs of ED 
11.5 as well as in/near the cardinal veins of ED 10.5 ( e , arrow-
heads) and ED 9.5 ( f , arrowheads) mouse embryos. Two serial 
 sections are shown in  a and  b .  a ,  b Scale bars = 50   m;  c–f scale 
bars = 20   m. Cell nuclei were counterstained with hematoxylin. 
a = Dorsal aorta; jls = jugular lymph sac; nt = neural tube; v = car-
dinal vein. 
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Table 1. B lockade of RAR- or of PKA inhibits the induction of Prox1+ cell clusters by RA and cAMP
Day 16 D ay 18
EBs1 clusters2 EBs1 clusters2
Control 0/9 0 0/9 0
10 M RA 0/9 0 0/9 0
10 M RA + 0.5 mM cAMP 9/9 3+1 9/9 1+0
10 M RA + 0.5 mM cAMP + 10 M Ro 41-5253 0/9 0 0/9 0
10 M RA + 0.5 mM cAMP + 10 M H89 0/9 0 0/9 0
0.5 mM cAMP 0/9 0 0/9 0
10 M Ro 41-5253 0/9 0 0/9 0
10 M H89 0/9 0 0/9 0
p = 0.11
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control
RA
LYVE-1+ area fraction (%)
Ro 41-5253
j
**
0
JLS area (μm2)
p = 0.19
p = 0.82
5.0 × 103
1.0 × 104
1.5 × 104
2.0 × 104
Vehicle 
control
RA Ro 41-5253
k
jls
jls
jls
jls
jls
v
v
v
v
v
v
jls
Vehicle control
Ro 41-5253
RA
a
b
c
d
e
f
g
h
i
 Fig. 5. In utero exposure of mouse embryos to excess of RA up-
regulates endothelial LYVE-1 expression in the anterior cardinal 
veins and jugular lymph sacs. Immunohistochemical analysis of 
paraffin sections from ED 11.5 mouse embryos for LYVE-1 re-
vealed that the endothelial cells of the anterior cardinal veins and 
of the forming lymph sacs up-regulated the expression of LYVE-1 
after in utero exposure to an excess of RA ( d – f and  j ), as compared 
with control embryos ( a ,  b , arrowheads,  c and  j ). Treatment with 
the RAR-  antagonist Ro 41-5253 decreased LYVE-1 expression 
(g –j ). The jugular lymph sac area was enlarged after RA treatment 
as compared to controls ( k ).  b ,  c ,  e ,  f ,  h and  i are sections of em-
bryos from two independent pregnant mice each.  a, d, g Scale
bars = 100   m;  b, e, h, c, f, i scale bars = 50   m. jls = Jugular lymph 
sac; nt = neural tube; v = cardinal vein. Data are expressed as mean 
values + SD (n = 4).  * *  p  ! 0.01. 
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
Fou r days of treatment with RA and cAMP induced the forma-
tion of 3+1 Prox1+/LYVE-1+/CD31+ cell clusters per EB. These 
clusters were found in 9 of 9 EBs analyzed. Ro 41-5253 (RAR- 
inhibitor) and H89 (PKA inhibitor) completely prevented the in-
duction of Prox1 endothelial cell clusters by RA and cAMP. No 
induction was seen after incubation with RA alone, cAMP alone 
or with the inhibitors alone.
1 Number of analyzed EBs. 2 Average number of CD31+/LYVE-
1+/Prox1+ cell clusters per EB + SD.
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 RA Upregulates Expression of LYVE-1 and VEGFR-3 
in the Vasculature of  X. laevis Embryos 
 Due to their small size, transparency and easy mainte-
nance,  X. laevis embryos are a useful animal model for 
studying development  [38] , particularly that of the lym-
phatic vasculature  [39, 40] .  Xenopus embryos were incu-
bated with RA and cAMP from stage 28, when the Prox1 
expression is first detected on the vasculature, until stage 
39, when lymphatic endothelial cells start to sprout from 
the lymph heart and the cardinal vein to form the first 
lymphatic vessels. In situ hybridization analyses revealed 
that exposure of the embryos to RA increased expression 
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 Fig. 6. In utero exposure of mouse embry-
os to excess of RA increases the number of 
Prox1-positive lymphatic progenitor cells 
in the cardinal veins and jugular lymph 
sac forming areas. Double-immunofluo-
rescence analysis of ED 11.5 mouse embry-
os exposed to excess RA ( g–l ) or vehicle 
( a–f ) for CD31 (cell membrane staining) 
and Prox1 (cell nucleus staining) revealed 
that RA exposure increased the number of 
Prox1+ endothelial cells in the anterior 
cardinal veins and in the area of the jugu-
lar lymph sacs as compared with control 
( r ). Ro 41-5253 treatment ( m– q ) slightly re-
duced the number of Prox1+/CD31+ cells 
in the jugular area as compared with con-
trol ( r ).  d–f ,  j–l and  p, q show representa-
tive sections of embryos from independent 
vehicle control, RA- or Ro 41-5253-treated 
pregnant mice, respectively. Cell nuclei are 
shown in  b ,  h ,  n .  a ,  b ,  g ,  h ,  m ,  n Scale
bars = 100   m;  c–f, i–l, o–q scale bars = 50 
  m. a = Dorsal aorta; jls = jugular lymph 
sac; nt = neural tube; v = cardinal vein. 
Data are expressed as mean values + SD
(n = 4).  * * *  p  ! 0.001. 
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 Fig. 7. Incubation of  X. laevis embryos with excess of RA downregulates CD31 and 
upregulates the lymphatic markers LYVE-1 and VEGFR-3 in the developing vas-
culature.  X. laevis tadpoles were bathed in RA in combination with cAMP ( b ,  d ,  f , 
 h , j ,  l ,  n ,  p ) or in DMSO ( a ,  c ,  e ,  g , i, k, m, o) from embryonic stages 28 to 39. In situ 
hybridization for CD31 ( a ,  b, i ,  j ), Prox1 ( c ,  d, k ,  l ), LYVE-1 ( e ,  f, m ,  n ) or VEGFR-3 
( g ,  h, o ,  p ) revealed that RA and cAMP reduced CD31 expression ( b ,  j ) in the de-
veloping vasculature, including intersomitic veins (isv), the cardinal vein (v) and 
the vitelline network (vn), compared with controls ( a, i ). No effects on Prox1 ex-
pression and/or distribution in the lymph heart (lh), lymphatic sprouts (ls) or in 
the lymphatic endothelial cells of venous origin (lv) were observed ( c ,  d, k ,  l ). In 
contrast, LYVE-1 expression was upregulated in the intersomitic veins and in the 
cardinal vein ( f , arrowheads,  n ) compared with controls ( e, m ). RA incubation also 
upregulated VEGFR-3 expression in the cardinal vein and vitelline network ( h , ar-
rowheads and asterisk, respectively,  p ) compared with  control embryos ( g , arrow-
heads, o). Scale bars = 50   m;  i–p scale bars = 5   m.  q Quantitative analysis of the 
number of VEGFR-3+ sprouts from the anterior cardinal vein following exposure 
to DMSO (vehicle) or the combination of RA and cAMP. Data are expressed as 
means + SEM (n = 150 per treatment group). 
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of VEGFR-3 ( fig. 7 g, h, o, p) and LYVE-1 ( fig. 7 e, f, m, n) 
throughout the developing vasculature, including the in-
tersomitic veins ( fig. 7 f, h, n, p, arrowheads), the cardinal 
vein ( fig.  7 f, h, n, p, arrows) and the vitelline network 
( fig. 7 h, asterisks), indicative of enhanced lymphatic com-
petence. Expression of CD31 was downregulated through-
out the entire vasculature ( fig. 7 a, b, i, j); this was an im-
portant observation because CD31 expression is reduced 
on lymphatic vessels, compared to blood vessels, during 
normal development. Prox1+ cells were found in the an-
terior and posterior cardinal veins, the tip of the tail, the 
lymph heart and the first sprouts from the lymph heart in 
both the RA-exposed and control embryos ( fig. 7 c, d, k, l). 
A quantitative analysis of the VEGFR-3 expression re-
vealed a significant increase in the number of VEGFR-3+ 
sprouts that developed from the anterior cardinal vein 
and the lymph heart following exposure to the combina-
tion of RA and cAMP, compared with controls (p = 0.002; 
 fig.  7 q). Only 16 + 5% of the control embryos had  1 5
VEGFR-3+ sprouts, compared to 54 + 5% of RA-exposed 
embryos. Moreover, in the embryos exposed to RA, VEG-
FR-3+ sprouts were longer than those of the control group 
( fig. 7 g, h, o, p).
 Discussion 
 This is the first demonstration that all-trans-RA is 
likely involved in the earliest steps of lymphatic vascular 
development, namely the acquisition of lymphatic com-
petence and commitment by endothelial cells of the em-
bryonic cardinal vein; RA appears to do so by upregulat-
ing the lymphatic markers LYVE-1 and Prox1.
 Our studies with the mouse EB vascular differentia-
tion assay found that VEGF-C, growth hormone, IGF-1 
and IL-7 increased the area of CD31+/LYVE-1+ vessel-
like structures in the EB assay; these findings are in 
agreement with the reported lymphangiogenic activity of 
growth hormone  [41] and IGF-1  [42] as well as the lym-
phatic reprogramming activity of IL-7 in cultured endo-
thelial cells  [43] . Most interestingly, however, we found 
that RA, alone and combination with cAMP, potently up-
regulated LYVE-1 expression in CD31+ vascular struc-
tures. The LYVE-1+, lymphatically competent endothe-
lial cells emerged from the pre-existing CD31+ blood vas-
cular endothelium, supporting the centrifugal theory of 
lymphatic vasculature development from pre-existing 
embryonic veins originally proposed by Sabin  [44] in 
1902. However, the combination of RA and cAMP also 
induced the formation of rare CD31+/LYVE-1+/Prox1+ 
cell clusters, independently from the CD31+ vessel-like 
networks. These findings indicate that mesenchymal 
progenitor cells might differentiate directly into lym-
phatically competent endothelial cells; this is in agree-
ment with the centripetal theory of mesenchyme-derived 
lymphatic progenitors proposed by Huntington and Mc-
Clure  [45] in 1910. The mouse EB vascular differentiation 
assay represents a suitable model for lymphatic vascula-
ture development in vivo, since lymphatic vessels in mice 
appear to be predominantly derived from pre-existing 
embryonic veins, as suggested by recent lineage-tracing 
studies  [46] , although there might be a contribution by 
mesenchyme-derived progenitor cells  [47, 48] . EB cells 
appear to be more responsive to the induction of lym-
phatic commitment than differentiated endothelial cells, 
since there was no induction of Prox1 by RA and cAMP 
in cultured HUVECs (online suppl. fig. S2C). In the same 
way, RA and cAMP treatment of cultured human um-
bilical vein endothelial cells did not induce the expression 
of Sox18 (data not shown). The absence of Prox1 and 
Sox18 induction in human umbilical vein endothelial 
cells, in a two-dimensional culture system, might indi-
cate the need for additional inducing factors derived from 
the microenvironment that are present in the EBs.
 RA binds to nuclear RARs, which after forming het-
erodimers with retinoid X receptors, activate histone acet-
ylation and gene transcription. Our finding that Ro 41-
5253 inhibited the induction of lymphatic vascular struc-
tures by RA indicated that the RA effect was mediated via 
RAR-  . Ro 41-5253 antagonizes the transactivation of 
RARs by RA, with a high affinity for RAR-  ; 50- to 100-
fold higher concentrations of Ro 41-5253 are required to 
reduce the activation of RAR-  and 1,000-fold higher con-
centrations are required to inhibit RAR-   [49] . The poten-
tiation of RA’s effects by cAMP and the inhibition by H89, 
a cAMP-dependent PKA inhibitor, indicate that the ef-
fects of RA are mediated by a pathway that includes cAMP 
and PKA  [50] , although we cannot completely exclude that 
H89, at the dose of 10   M used, might also have exerted 
some off-target effects, even though H89 alone had no de-
tectable effects. Indeed, it has been found that RA and 
cAMP have synergistic effects in  several differentiation 
processes including neural  [36] , smooth muscle  [35] and 
endothelial progenitor cell  [34] differentiation, although 
the precise mechanisms of RA and cAMP interaction re-
main to be established. This concept is supported by our 
in silico analyses; the Ali Baba (http://www.gene-regula-
tion.com/pub/programs.html), PROMO (http://alggen.
lsi.upc.es/cgi-bin/promo_v3/ promo/promoinit.cgi?
dirDB=TF_8.3) and TESS (http://www.cbil.upenn.edu/
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cgi-bin/tess/tess) software indicate that retinoid X recep-
tors and RARs, as well as cAMP response element-binding 
proteins, bind to the promoter regions of the mouse LYVE-
1 and Prox1 genes (data not shown).
 The role of retinoid signaling in the mediation of lym-
phatic competence is supported by immunohistochemi-
cal analyses showing that RAR-  is strongly expressed by 
the endothelial cells of the embryonic cardinal veins at 
ED 9.5, when lymphatic competence and commitment 
are first detected and at EDs 10.5 and 11.5, when LEC 
progenitors bud off from the cardinal vein  [8, 11] . The 
finding that at EDs 9.5 and 10.5, RAR-  was also ex-
pressed by some cells in clusters near cardinal veins rais-
es the possibility that surrounding cells might contribute, 
by indirect effects, to the induction of lymphatic compe-
tence by RA. However, our observation that incubation 
of human umbilical vein endothelial cells with RA in-
creased LYVE-1 mRNA expression by  1 2-fold (p = 0.042; 
online suppl. fig. S2A) and also increased LYVE-1 protein 
levels (online suppl. fig. S2B, C), suggests that the effects 
of RA are directly mediated by endothelial cells.
 To investigate whether RA also promotes lymphatic 
competence and commitment in vivo, we used estab-
lished models of  Xenopus and mouse lymphatic develop-
ment. Previous studies have shown that excess or lack of 
RA during early embryogenesis causes malformations 
 [51, 52] , through mispatterning of the embryonic tissue 
layers and the anterior-posterior body axis. Several RAR 
knockout mice have been created  [53] . Together, RAR de-
ficiency and vitamin A deprivation lead to a plethora of 
embryonic defects, including those of the eye, respiratory 
tract, heart, kidney, genital tract, bones and limbs, as well 
as axial skeletal and neural malformations  [26] . Impor-
tantly, however, vitamin A deficiency is also associated 
with cardiovascular problems and enlargement of the an-
terior cardinal veins in rat embryos  [27, 28] . Zebrafish 
that express mutant forms of the RA-metabolizing en-
zyme Cyp26A1 also display patterning defects in multi-
ple organs, including the common cardinal vein, pectoral 
fin, tail, hindbrain and spinal cord. Because of the multi-
tude of developmental defects caused by RA deficiency or 
exposure  [54–58] , we investigated the in vivo effects of 
RA exposure over only short time periods and during the 
earliest phases of lymphatic development.
 Importantly in mice, increased levels of RA in utero 
upregulated LYVE-1 expression in the endothelial cells of 
the anterior part of the cardinal veins and of the forming 
lymph sacs (which also slightly increased in size). An in-
creased number of CD31+/Prox1+ endothelial cells was 
detected in the cardinal veins and the developing lymph 
sacs. In contrast, in utero injection of Ro 41-5253, a spe-
cific inhibitor of RAR-  signaling  [49] , reduced LYVE-1 
expression and decreased the number of CD31+/Prox1+ 
cells in the jugular area of the ED 11.5 embryos. However, 
the extent of inhibition was rather mild and the quantita-
tive evaluation did not reach a significance level of 0.05, 
in part due to the rather high variability among the dif-
ferent embryos. Other possible explanations for these 
findings are (1) a potential compensatory role of RAR-  
and/or RAR-   [59] ; (2) noncanonical activity of RA via 
CREB or ERK  [60] , and (3) an incomplete blockade of 
RAR-  activity by the two injections of Ro 41-5253.
 Exposure of stage 28–39  Xenopus embryos to RA 
downregulated CD31 expression but enhanced expres-
sion of VEGFR-3 and LYVE-1 in the developing vascula-
ture, mainly in the intersomitic veins, the cardinal vein 
and the vitelline vein network. Because incubation of 
 Xenopus embryos with different concentrations of Ro 41-
5253 induced lethality of stage 28 tadpoles (data not 
shown), the vascular effects of specific blockade of RAR-
  could not be evaluated in the  Xenopus model. In addi-
tion, morpholino knockdown experiments would not 
represent a suitable loss-of-function approach since it has 
been shown that knockdown of either RAR-  1 or RAR-
  2 (or both) leads to a severe phenotype in  Xenopus em-
bryos, mainly regarding the head formation, already at 
the early stage 20 (the first Prox1 expression in Xenopus 
is at stage 28)  [61] .
 All-trans-RA and its derivatives exert many different 
and often contradictory effects on cells, depending on 
context, cell type and other variables; its role in angiogen-
esis, for example, remains controversial so far. It is has 
been found that RA induces in vitro tube formation of 
HUVECs  [62] via a possible paracrine effect by inducing 
endogenous VEGFA and fibroblast growth factor-2 pro-
duction as well as angiogenesis in bovine aortic endothe-
lial cells in vitro  [63] . On the other hand, RA caused en-
dothelial cells to become refractory to stimulation by 
 either tumor-conditioned media or various angiogenic 
factors without interfering with cell proliferation  [64] . In 
addition, there is evidence that the antitumor activity of 
retinoids involves inhibition of tumor-induced angiogen-
esis  [64–66] .
 Interactions between retinoid signaling and Prox1 ex-
pression have been described during other aspects of de-
velopment. RA modulates Prox1 expression in the dorsal 
endoderm of mouse embryos  [67] and promotes neuronal 
progenitor cell differentiation into retinal  [68] or cochle-
ar cells  [69] , which express Prox1  [69–72] . Development 
of the murine liver also appears to be RA dependent  [73] 
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